2014 Q2 Form 10-Q Financial Statement
#000110465914035805 Filed on May 07, 2014
Income Statement
| Concept | 2014 Q2 | 2014 Q1 | 2013 Q1 |
|---|---|---|---|
| Revenue | $934.0K | $165.0K | $1.344M |
| YoY Change | -29.35% | -87.72% | -98.94% |
| Cost Of Revenue | $188.0K | $0.00 | |
| YoY Change | |||
| Gross Profit | -$23.00K | $1.344M | |
| YoY Change | -101.71% | ||
| Gross Profit Margin | -13.94% | 100.0% | |
| Selling, General & Admin | $8.600M | $22.83M | $8.315M |
| YoY Change | 48.28% | 174.61% | 5.25% |
| % of Gross Profit | 618.68% | ||
| Research & Development | $2.125M | $43.39M | $26.42M |
| YoY Change | -11.9% | 64.25% | -20.44% |
| % of Gross Profit | 1965.48% | ||
| Depreciation & Amortization | $2.800M | $3.400M | $1.898M |
| YoY Change | 40.0% | 79.14% | -0.63% |
| % of Gross Profit | 141.22% | ||
| Operating Expenses | $10.73M | $66.41M | $34.73M |
| YoY Change | 30.51% | 91.21% | -15.41% |
| Operating Profit | -$9.794M | -$66.24M | -$33.39M |
| YoY Change | 41.98% | 98.41% | -138.8% |
| Interest Expense | $10.33M | $1.644M | $2.736M |
| YoY Change | 241.39% | -39.91% | 82.16% |
| % of Operating Profit | |||
| Other Income/Expense, Net | $83.00K | -$3.000K | -$1.422M |
| YoY Change | -98.99% | -99.79% | |
| Pretax Income | -$19.87M | -$16.20M | -$10.70M |
| YoY Change | 1189.62% | 51.4% | -112.65% |
| Income Tax | $278.0K | $0.00 | $0.00 |
| % Of Pretax Income | |||
| Net Earnings | -$63.60M | -$67.70M | -$37.40M |
| YoY Change | 74.73% | 81.02% | -144.21% |
| Net Earnings / Revenue | -6809.42% | -41030.3% | -2782.74% |
| Basic Earnings Per Share | -$0.39 | ||
| Diluted Earnings Per Share | -$573.0K | -$611.6K | -$0.39 |
| COMMON SHARES | |||
| Basic Shares Outstanding | 112.6M shares | 112.0M shares | 96.38M shares |
| Diluted Shares Outstanding | 96.38M shares |
Balance Sheet
| Concept | 2014 Q2 | 2014 Q1 | 2013 Q1 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $334.5M | $370.9M | $459.1M |
| YoY Change | -24.5% | -19.2% | 129.3% |
| Cash & Equivalents | $208.1M | $125.3M | $266.1M |
| Short-Term Investments | $126.4M | $245.6M | $193.0M |
| Other Short-Term Assets | $15.20M | $6.400M | $5.200M |
| YoY Change | 322.22% | 23.08% | 33.33% |
| Inventory | $0.00 | $11.01M | $8.049M |
| Prepaid Expenses | |||
| Receivables | $0.00 | $3.000K | $2.200M |
| Other Receivables | $0.00 | $0.00 | $0.00 |
| Total Short-Term Assets | $353.2M | $389.2M | $474.5M |
| YoY Change | -22.76% | -17.98% | 132.26% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $0.00 | $9.734M | $9.010M |
| YoY Change | -100.0% | 8.04% | -10.79% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | $34.30M | $59.80M | $99.30M |
| YoY Change | -62.02% | -39.78% | |
| Other Assets | $22.39M | $7.963M | $7.682M |
| YoY Change | 203.65% | 3.66% | 140.06% |
| Total Long-Term Assets | $252.4M | $215.8M | $117.0M |
| YoY Change | 83.64% | 84.47% | 773.19% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $353.2M | $389.2M | $474.5M |
| Total Long-Term Assets | $252.4M | $215.8M | $117.0M |
| Total Assets | $605.6M | $605.0M | $591.5M |
| YoY Change | 1.83% | 2.28% | 171.71% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $1.799M | $5.546M | $3.525M |
| YoY Change | -62.78% | 57.33% | -33.49% |
| Accrued Expenses | $16.90M | $29.80M | $16.10M |
| YoY Change | -31.85% | 85.09% | 11.03% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | |||
| YoY Change | |||
| Total Short-Term Liabilities | $49.99M | $44.14M | $29.46M |
| YoY Change | 29.36% | 49.82% | 15.09% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $737.5M | $287.5M | $460.0M |
| YoY Change | 60.33% | -37.5% | 166.67% |
| Other Long-Term Liabilities | $1.300M | $10.10M | $10.50M |
| YoY Change | -87.62% | -3.81% | -22.22% |
| Total Long-Term Liabilities | $1.300M | $297.6M | $470.5M |
| YoY Change | -99.72% | -36.75% | 152.96% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $49.99M | $44.14M | $29.46M |
| Total Long-Term Liabilities | $1.300M | $297.6M | $470.5M |
| Total Liabilities | $51.29M | $341.8M | $500.0M |
| YoY Change | -89.92% | -31.64% | 136.29% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$1.636B | -$1.573B | -$1.372B |
| YoY Change | 16.2% | 14.65% | |
| Common Stock | $1.445B | $1.836B | $1.463B |
| YoY Change | -3.26% | 25.47% | |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | -$187.5M | $263.3M | $91.51M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $605.6M | $605.0M | $591.5M |
| YoY Change | 1.83% | 2.28% | 171.71% |
Cashflow Statement
| Concept | 2014 Q2 | 2014 Q1 | 2013 Q1 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$63.60M | -$67.70M | -$37.40M |
| YoY Change | 74.73% | 81.02% | -144.21% |
| Depreciation, Depletion And Amortization | $2.800M | $3.400M | $1.898M |
| YoY Change | 40.0% | 79.14% | -0.63% |
| Cash From Operating Activities | -$54.40M | -$50.60M | -$31.60M |
| YoY Change | 225.75% | 60.13% | -23.49% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | -$44.00M | $1.620M | $740.0K |
| YoY Change | 43.32% | 118.92% | -32.91% |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | $32.70M | $70.80M | -$44.30M |
| YoY Change | -176.4% | -259.82% | -566.32% |
| Cash From Investing Activities | -$11.20M | $14.10M | -$45.00M |
| YoY Change | -84.76% | -131.33% | -635.71% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | $18.27M | $2.991M | |
| YoY Change | 510.9% | 18.13% | |
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 148.4M | 18.30M | 247.9M |
| YoY Change | 534.19% | -92.62% | 9816.0% |
| NET CHANGE | |||
| Cash From Operating Activities | -54.40M | -50.60M | -31.60M |
| Cash From Investing Activities | -11.20M | 14.10M | -45.00M |
| Cash From Financing Activities | 148.4M | 18.30M | 247.9M |
| Net Change In Cash | 82.80M | -18.20M | 171.3M |
| YoY Change | -223.95% | -110.62% | -663.49% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$54.40M | -$50.60M | -$31.60M |
| Capital Expenditures | -$44.00M | $1.620M | $740.0K |
| Free Cash Flow | -$10.40M | -$52.22M | -$32.34M |
| YoY Change | -174.29% | 61.47% | -23.73% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2014Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
109859000 | shares |
| CY2013Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
96379000 | shares |
| CY2014Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.62 | |
| CY2013Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.39 | |
| CY2014Q1 | us-gaap |
Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
|
112052000 | shares |
| CY2013Q1 | us-gaap |
Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
|
99181000 | shares |
| CY2014Q1 | us-gaap |
Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
|
2193000 | shares |
| CY2013Q1 | us-gaap |
Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
|
2802000 | shares |
| CY2014Q1 | us-gaap |
Revenue Recognition Accounting Policy Gross And Net Revenue Disclosure
RevenueRecognitionAccountingPolicyGrossAndNetRevenueDisclosure
|
<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"><i><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Product Revenues</font></i></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">We sell VIBATIV</font><font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1">®</font><font style="FONT-SIZE: 10pt;" size="2"> in the U.S. through a limited number of distributors, and title and risk of loss transfer upon receipt by these distributors. Healthcare providers order VIBATIV</font><font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1">®</font><font style="FONT-SIZE: 10pt;" size="2"> through these distributors. Commencing in the first quarter of 2014, we record revenue on the sale of VIBATIV</font><font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1">®</font> <font style="FONT-SIZE: 10pt;" size="2">on a sell-through basis, once the distributors sell the product to healthcare providers.</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Product sales are recorded net of estimated government-mandated rebates and chargebacks, distribution fees, estimated product returns and other deductions. We reflect such reductions in revenue as either an allowance to the related account receivable from the distributor, or as an accrued liability, depending on the nature of the sales deduction. Sales deductions are based on management’s estimates that consider payer mix in target markets, industry benchmarks and experience to date. We monitor inventory levels in the distribution channel, as well as sales of VIBATIV</font><font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1">®</font><font style="FONT-SIZE: 10pt;" size="2"> by distributors to healthcare providers, using product-specific data provided by the distributors. Product return allowances are based on amounts owed or to be claimed on related sales. These estimates take into consideration the terms of our agreements with customers, historical product returns of VIBATIV</font><font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1">®</font><font style="FONT-SIZE: 10pt;" size="2"> experienced by our former collaborative partner, Astellas, rebates or discounts taken, estimated levels of inventory in the distribution channel, the shelf life of the product, and specific known market events, such as competitive pricing and new product introductions. We update our estimates and assumptions each quarter and if actual future results vary from our estimates, we may adjust these estimates, which could have an effect on product sales and earnings in the period of adjustment.</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><i><u><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Sales Discounts:</font></u></i><font style="FONT-SIZE: 10pt;" size="2">  We offer cash discounts to our customers, generally 2% of the sales price, as an incentive for prompt payment. We expect our customers to comply with the prompt payment terms to earn the cash discount. We account for cash discounts by reducing accounts receivable by the full amount and recognizing the discount as a reduction of revenue in the same period the related revenue is recognized.</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><i><u><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Chargebacks and Government Rebates:</font></u></i><font style="FONT-SIZE: 10pt;" size="2">  For VIBATIV</font><font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1">®</font><font style="FONT-SIZE: 10pt;" size="2"> sales in the U.S., we estimate reductions to product sales for qualifying federal and state government programs including discounted pricing offered to Public Health Service (PHS) as well as government-managed Medicaid programs. Our reduction for PHS is based on actual chargebacks that distributors have claimed for reduced pricing offered to such health care providers. Our accrual for Medicaid is based upon statutorily-defined discounts, estimated payer mix, expected sales to qualified healthcare providers, and our expectation about future utilization. The Medicaid accrual and government rebates that are invoiced directly to us are recorded in other accrued liabilities on the consolidated balance sheet. For qualified programs that can purchase our products through distributors at a lower contractual government price, the distributors charge back to us the difference between their acquisition cost and the lower contractual government price, which we record as an allowance against accounts receivable.</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><i><u><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Distribution Fees and Product Returns:</font></u></i><font style="FONT-SIZE: 10pt;" size="2">  We have written contracts with our distributors that include terms for distribution-related fees. We record distribution-related fees based on a percentage of the product sales price. We offer our distributors a right to return product purchased directly from us, which is principally based upon the product’s expiration date. Additionally, we have granted more expansive return rights to our distributors following our product launch of VIBATIV</font><font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1">®</font><font style="FONT-SIZE: 10pt;" size="2">. We will generally accept returns for expired product during the six months prior to and twelve months after the product expiration date on product that had been sold to our distributors. Product returned is generally not resalable given the nature of our products and method of administration. We have developed estimates for VIBATIV</font><font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1">®</font><font style="FONT-SIZE: 10pt;" size="2"> product returns based upon historical VIBATIV</font><font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1">®</font><font style="FONT-SIZE: 10pt;" size="2"> sales from our former collaborative partner, Astellas. We record distribution fees and product returns as an allowance against accounts receivable.</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><i><u><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Allowance for Doubtful Accounts:</font></u></i><font style="FONT-SIZE: 10pt;" size="2">  We maintain a policy to record allowances for potentially doubtful accounts for estimated losses resulting from the inability of our customers to make required payments. As of March 31, 2014 and December 31, 2013, there was no allowance for doubtful accounts.</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"> </p> </div> | |
| CY2013Q2 | thrx |
Number Of Independent Publicly Traded Companies Created By Separation Of Businesses As Approved By Board Of Directors
NumberOfIndependentPubliclyTradedCompaniesCreatedBySeparationOfBusinessesAsApprovedByBoardOfDirectors
|
2 | Item |
| CY2014Q1 | us-gaap |
Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
|
0 | USD |
| CY2013Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
|
0 | USD |
| CY2014Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
5991000 | shares |
| CY2013Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
19725000 | shares |
| CY2014Q1 | us-gaap |
Revenues
Revenues
|
165000 | USD |
| CY2013Q1 | us-gaap |
Revenues
Revenues
|
1344000 | USD |
| CY2014Q1 | thrx |
Collaborative Arrangement Research And Development Expenses Reimbursed To Entity
CollaborativeArrangementResearchAndDevelopmentExpensesReimbursedToEntity
|
133000 | USD |
| CY2013Q1 | thrx |
Collaborative Arrangement Research And Development Expenses Reimbursed To Entity
CollaborativeArrangementResearchAndDevelopmentExpensesReimbursedToEntity
|
2134000 | USD |
| CY2014Q1 | thrx |
Marketable Securities Maximum Contractual Maturity Period
MarketableSecuritiesMaximumContractualMaturityPeriod
|
P2Y | |
| CY2014Q1 | thrx |
Marketable Securities Average Contractual Maturity Period
MarketableSecuritiesAverageContractualMaturityPeriod
|
P7M | |
| CY2014Q1 | us-gaap |
Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
|
5000000 | USD |
| CY2013Q1 | us-gaap |
Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
|
5000000 | USD |
| CY2013Q4 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
502831000 | USD |
| CY2013Q4 | us-gaap |
Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
|
502669000 | USD |
| CY2014Q1 | us-gaap |
Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
|
425301000 | USD |
| CY2014Q1 | thrx |
Available For Sale Securities Gross Unrealized Gain Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
|
181000 | USD |
| CY2013Q4 | thrx |
Available For Sale Securities Gross Unrealized Loss Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
|
10000 | USD |
| CY2014Q1 | thrx |
Available For Sale Securities Gross Unrealized Loss Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
|
10000 | USD |
| CY2014Q1 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
425472000 | USD |
| CY2013Q4 | thrx |
Available For Sale Securities Gross Unrealized Gain Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
|
172000 | USD |
| CY2014Q1 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
4891000 | USD |
| CY2013Q4 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
5138000 | USD |
| CY2013Q4 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
360000 | USD |
| CY2013Q4 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
4908000 | USD |
| CY2013Q4 | us-gaap |
Inventory Net
InventoryNet
|
10406000 | USD |
| CY2014Q1 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
3997000 | USD |
| CY2014Q1 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
2225000 | USD |
| CY2014Q1 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
4792000 | USD |
| CY2014Q1 | us-gaap |
Inventory Net
InventoryNet
|
11014000 | USD |
| CY2014Q1 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
|
8100000 | USD |
| CY2014Q1 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
|
9100000 | USD |
| CY2014Q1 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
|
9100000 | USD |
| CY2014Q1 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
|
9100000 | USD |
| CY2014Q1 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
|
9100000 | USD |
| CY2014Q1 | us-gaap |
Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
|
94700000 | USD |
| CY2014Q1 | dei |
Amendment Flag
AmendmentFlag
|
false | |
| CY2014Q1 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
| CY2013Q4 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
4774000 | USD |
| CY2014Q1 | us-gaap |
Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
|
5247000 | USD |
| CY2013Q4 | us-gaap |
Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
|
5455000 | USD |
| CY2013Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2014Q1 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2014Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
1125000 | USD |
| CY2014Q1 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
| CY2014Q1 | dei |
Entity Filer Category
EntityFilerCategory
|
Large Accelerated Filer | |
| CY2014Q2 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
112633882 | shares |
| CY2014Q1 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2014 | |
| CY2014Q1 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q1 | |
| CY2013Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
1115000 | USD |
| CY2014Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
125275000 | USD |
| CY2013Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
143510000 | USD |
| CY2014Q1 | us-gaap |
Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
|
245648000 | USD |
| CY2013Q4 | us-gaap |
Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
|
321615000 | USD |
| CY2014Q1 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
3000 | USD |
| CY2013Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
199000 | USD |
| CY2014Q1 | thrx |
Receivables From Collaboration Partners
ReceivablesFromCollaborationPartners
|
865000 | USD |
| CY2014Q1 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
1834862000 | USD |
| CY2013Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
1803048000 | USD |
| CY2014Q1 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
171000 | USD |
| CY2013Q4 | thrx |
Receivables From Collaboration Partners
ReceivablesFromCollaborationPartners
|
3181000 | USD |
| CY2014Q1 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
6391000 | USD |
| CY2013Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
4287000 | USD |
| CY2014Q1 | us-gaap |
Assets Current
AssetsCurrent
|
389196000 | USD |
| CY2014Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
13535000 | USD |
| CY2013Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
6095000 | USD |
| CY2013Q1 | us-gaap |
Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
|
100000 | USD |
| CY2014Q1 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
433000 | shares |
| CY2014Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
15.34 | |
| CY2014Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
6636000 | USD |
| CY2014Q1 | dei |
Entity Registrant Name
EntityRegistrantName
|
THERAVANCE INC | |
| CY2014Q1 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001080014 | |
| CY2014Q1 | dei |
Document Type
DocumentType
|
10-Q | |
| CY2014Q1 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2014-03-31 | |
| CY2013Q4 | us-gaap |
Assets Current
AssetsCurrent
|
483198000 | USD |
| CY2014Q1 | us-gaap |
Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
|
59831000 | USD |
| CY2013Q4 | us-gaap |
Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
|
55374000 | USD |
| CY2014Q1 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
833000 | USD |
| CY2013Q4 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
833000 | USD |
| CY2014Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
9734000 | USD |
| CY2013Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
10238000 | USD |
| CY2014Q1 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
137477000 | USD |
| CY2013Q4 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
124257000 | USD |
| CY2014Q1 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
7963000 | USD |
| CY2013Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
7355000 | USD |
| CY2014Q1 | us-gaap |
Assets
Assets
|
605034000 | USD |
| CY2013Q4 | us-gaap |
Assets
Assets
|
681255000 | USD |
| CY2014Q1 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
5546000 | USD |
| CY2013Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
7583000 | USD |
| CY2013Q4 | us-gaap |
Due To Related Parties Current
DueToRelatedPartiesCurrent
|
40000000 | USD |
| CY2013Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
162000 | USD |
| CY2014Q1 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
13829000 | USD |
| CY2013Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
10881000 | USD |
| CY2014Q1 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
9890000 | USD |
| CY2013Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
9714000 | USD |
| CY2014Q1 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
1273000 | USD |
| CY2014Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-1572906000 | USD |
| CY2013Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-1505203000 | USD |
| CY2014Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
263252000 | USD |
| CY2013Q4 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
2800000 | USD |
| CY2014Q1 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
4792000 | USD |
| CY2013Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
4137000 | USD |
| CY2014Q1 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
8814000 | USD |
| CY2013Q4 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
9289000 | USD |
| CY2014Q1 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
44144000 | USD |
| CY2013Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
84404000 | USD |
| CY2014Q1 | us-gaap |
Convertible Subordinated Debt Noncurrent
ConvertibleSubordinatedDebtNoncurrent
|
287500000 | USD |
| CY2013Q4 | us-gaap |
Convertible Subordinated Debt Noncurrent
ConvertibleSubordinatedDebtNoncurrent
|
287500000 | USD |
| CY2013Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
299122000 | USD |
| CY2014Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
605034000 | USD |
| CY2013Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
681255000 | USD |
| CY2014Q1 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
209000 | USD |
| CY2013Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
89000 | USD |
| CY2014Q1 | us-gaap |
Due From Related Parties Current
DueFromRelatedPartiesCurrent
|
775000 | USD |
| CY2013Q4 | us-gaap |
Due From Related Parties Current
DueFromRelatedPartiesCurrent
|
2247000 | USD |
| CY2014Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.01 | |
| CY2013Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.01 | |
| CY2014Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
200000000 | shares |
| CY2013Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
111516000 | shares |
| CY2013Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
200000000 | shares |
| CY2014Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
112519000 | shares |
| CY2014Q1 | thrx |
Royalty Revenue From Related Party Net
RoyaltyRevenueFromRelatedPartyNet
|
-1050000 | USD |
| CY2014Q1 | thrx |
Collaborative Arrangements Revenue
CollaborativeArrangementsRevenue
|
270000 | USD |
| CY2013Q1 | thrx |
Collaborative Arrangements Revenue
CollaborativeArrangementsRevenue
|
1344000 | USD |
| CY2014Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
43387000 | USD |
| CY2013Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
26416000 | USD |
| CY2014Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
66409000 | USD |
| CY2013Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
34731000 | USD |
| CY2014Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-66244000 | USD |
| CY2013Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-33387000 | USD |
| CY2014Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-3000 | USD |
| CY2013Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-1422000 | USD |
| CY2014Q1 | us-gaap |
Investment Income Net
InvestmentIncomeNet
|
188000 | USD |
| CY2013Q1 | us-gaap |
Investment Income Net
InvestmentIncomeNet
|
185000 | USD |
| CY2014Q1 | us-gaap |
Interest Expense
InterestExpense
|
1644000 | USD |
| CY2013Q1 | us-gaap |
Interest Expense
InterestExpense
|
2736000 | USD |
| CY2014Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
1780000 | USD |
| CY2013Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
0 | USD |
| CY2014Q1 | us-gaap |
Revenue From Related Parties
RevenueFromRelatedParties
|
270000 | USD |
| CY2013Q1 | us-gaap |
Revenue From Related Parties
RevenueFromRelatedParties
|
1322000 | USD |
| CY2014Q1 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
9000 | USD |
| CY2013Q1 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
-7000 | USD |
| CY2014Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-67694000 | USD |
| CY2013Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-37367000 | USD |
| CY2014Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
3400000 | USD |
| CY2013Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
1898000 | USD |
| CY2013Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
6095000 | USD |
| CY2014Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
13535000 | USD |
| CY2013Q1 | us-gaap |
Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
|
-1422000 | USD |
| CY2014Q1 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
2000 | USD |
| CY2013Q1 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
1000 | USD |
| CY2014Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
178000 | USD |
| CY2014Q1 | us-gaap |
Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
|
-2316000 | USD |
| CY2013Q1 | us-gaap |
Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
|
1153000 | USD |
| CY2014Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
2132000 | USD |
| CY2013Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
1224000 | USD |
| CY2014Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
430000 | USD |
| CY2013Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
2481000 | USD |
| CY2014Q1 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
998000 | USD |
| CY2014Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-1174000 | USD |
| CY2013Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-221000 | USD |
| CY2014Q1 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
4448000 | USD |
| CY2013Q1 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-3176000 | USD |
| CY2014Q1 | us-gaap |
Debt Instrument Increase Accrued Interest
DebtInstrumentIncreaseAccruedInterest
|
1527000 | USD |
| CY2013Q1 | us-gaap |
Debt Instrument Increase Accrued Interest
DebtInstrumentIncreaseAccruedInterest
|
174000 | USD |
| CY2014Q1 | us-gaap |
Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
|
-116000 | USD |
| CY2013Q1 | us-gaap |
Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
|
202000 | USD |
| CY2014Q1 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-308000 | USD |
| CY2013Q1 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
4946000 | USD |
| CY2014Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-50637000 | USD |
| CY2013Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-31631000 | USD |
| CY2014Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
1620000 | USD |
| CY2013Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
740000 | USD |
| CY2014Q1 | us-gaap |
Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
|
56649000 | USD |
| CY2013Q1 | us-gaap |
Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
|
104125000 | USD |
| CY2014Q1 | us-gaap |
Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
|
122399000 | USD |
| CY2013Q1 | us-gaap |
Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
|
54753000 | USD |
| CY2014Q1 | us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
55000000 | USD |
| CY2013Q1 | us-gaap |
Proceeds From Sale And Collection Of Notes Receivable
ProceedsFromSaleAndCollectionOfNotesReceivable
|
100000 | USD |
| CY2014Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
14130000 | USD |
| CY2013Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-45012000 | USD |
| CY2014Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
18272000 | USD |
| CY2013Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
2991000 | USD |
| CY2013Q1 | us-gaap |
Payments For Derivative Instrument Financing Activities
PaymentsForDerivativeInstrumentFinancingActivities
|
36800000 | USD |
| CY2013Q1 | us-gaap |
Proceeds From Issuance Of Subordinated Long Term Debt
ProceedsFromIssuanceOfSubordinatedLongTermDebt
|
281673000 | USD |
| CY2014Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
18272000 | USD |
| CY2013Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
247864000 | USD |
| CY2014Q1 | us-gaap |
Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
|
-18235000 | USD |
| CY2013Q1 | us-gaap |
Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
|
171221000 | USD |
| CY2012Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
94849000 | USD |
| CY2013Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
266070000 | USD |
| CY2014Q1 | us-gaap |
Sales Revenue Goods Net
SalesRevenueGoodsNet
|
945000 | USD |
| CY2014Q1 | us-gaap |
Cost Of Goods Sold
CostOfGoodsSold
|
188000 | USD |
| CY2014Q1 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
22834000 | USD |
| CY2013Q1 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
8315000 | USD |
| CY2014Q1 | thrx |
Collaborative Arrangements And Royalty Revenue
CollaborativeArrangementsAndRoyaltyRevenue
|
-780000 | USD |
| CY2013Q1 | thrx |
Collaborative Arrangements And Royalty Revenue
CollaborativeArrangementsAndRoyaltyRevenue
|
1344000 | USD |
| CY2014Q1 | us-gaap |
Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
|
P15Y | |
| CY2014Q1 | us-gaap |
Revenue Recognition Services Royalty Fees
RevenueRecognitionServicesRoyaltyFees
|
<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"><i><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Royalties</font></i></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">We recognize royalty revenue on licensee net sales of our products in the period in which the royalties are earned and reported to us and collectability is reasonably assured.</font></p> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"> </p> </div> | |
| CY2014Q1 | us-gaap |
Due To Related Parties Current
DueToRelatedPartiesCurrent
|
0 | USD |
| CY2013Q1 | us-gaap |
Sales Revenue Goods Net
SalesRevenueGoodsNet
|
0 | USD |
| CY2013Q1 | thrx |
Royalty Revenue From Related Party Net
RoyaltyRevenueFromRelatedPartyNet
|
0 | USD |
| CY2013Q1 | us-gaap |
Cost Of Goods Sold
CostOfGoodsSold
|
0 | USD |
| CY2014Q1 | us-gaap |
Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
|
0 | USD |
| CY2013Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
0 | USD |
| CY2013Q1 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
0 | USD |
| CY2013Q1 | us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
0 | USD |
| CY2014Q1 | us-gaap |
Proceeds From Sale And Collection Of Notes Receivable
ProceedsFromSaleAndCollectionOfNotesReceivable
|
0 | USD |
| CY2014Q1 | us-gaap |
Payments For Derivative Instrument Financing Activities
PaymentsForDerivativeInstrumentFinancingActivities
|
0 | USD |
| CY2014Q1 | us-gaap |
Proceeds From Issuance Of Subordinated Long Term Debt
ProceedsFromIssuanceOfSubordinatedLongTermDebt
|
0 | USD |
